Citadel Advisors’s MaxCyte MXCT Stock Holding History

Citadel Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,700	Closed	-$36.2K	–	15209
2024 Q4	$36.2K	Buy	8,700 +7,700	+770%	+$29.1K	﹤0.01%	12704
2024 Q3	$3.89K	Buy	1,000 +400	+67%	+$1.69K	﹤0.01%	13618
2024 Q2	$2.35K	Sell	600 -1,800	-75%	-$7.74K	﹤0.01%	13696
2024 Q1	$10.1K	Buy	+2,400	New	+$11.3K	﹤0.01%	13474
2023 Q4	–	Sell	-900	Closed	-$2.81K	–	14898
2023 Q3	$2.81K	Sell	900 -100	-10%	-$402	﹤0.01%	13670
2023 Q2	$4.59K	Sell	1,000 -1,900	-66%	-$8.73K	﹤0.01%	13585
2023 Q1	$14.4K	Sell	2,900 -600	-17%	-$2.96K	﹤0.01%	13316
2022 Q4	$19.1K	Sell	3,500 -8,900	-72%	-$54.6K	﹤0.01%	13186
2022 Q3	$81K	Buy	12,400 +200	+2%	+$1.12K	﹤0.01%	11274
2022 Q2	$58K	Buy	+12,200	New	+$60.1K	﹤0.01%	11842

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

Citadel Advisors's MXCT Position: Q1 2026 in Review

Citadel Advisors reduced its MaxCyte (MXCT) stake by 78% in Q1 2026, selling an estimated $1.08M and leaving 333,088 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #11068.

Citadel Advisors first reported a position in MXCT in Q4 2021 and has held it in 18 quarters since. The position peaked at $11.6M in Q4 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

Citadel Advisors held 333,088 shares of MaxCyte worth $234K as of Q1 2026.
Citadel Advisors sold 1,155,730 MaxCyte shares in Q1 2026, an estimated $1.08M.
MaxCyte made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11068 holding.
Citadel Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 18 quarters since.
Citadel Advisors's MaxCyte position peaked at $11.6M in Q4 2022.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.